Voloridge Investment Management’s Heron Therapeutics HRTX Stock Holding History

Voloridge Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,933	Closed	-$128K	–	1683
2021 Q3	$128K	Buy	+11,933	New	+$145K	﹤0.01%	1604
2020 Q4	–	Sell	-48,814	Closed	-$723K	–	1426
2020 Q3	$723K	Buy	+48,814	New	+$762K	0.01%	1019
2020 Q1	–	Sell	-168,614	Closed	-$3.96M	–	1220
2019 Q4	$3.96M	Buy	168,614 +143,683	+576%	+$3.18M	0.08%	331
2019 Q3	$461K	Sell	24,931 -45,086	-64%	-$830K	0.01%	824
2019 Q2	$1.3M	Buy	+70,017	New	+$1.4M	0.04%	401
2018 Q3	–	Sell	-21,227	Closed	-$825K	–	369
2018 Q2	$825K	Sell	21,227 -81,627	-79%	-$2.6M	0.02%	332
2018 Q1	$2.84M	Buy	+102,854	New	+$2.33M	0.07%	238
2015 Q4	–	Sell	-52,500	Closed	-$1.28M	–	236
2015 Q3	$1.28M	Sell	52,500 -36,658	-41%	-$1.22M	0.06%	207
2015 Q2	$2.78M	Buy	+89,158	New	+$1.68M	0.14%	152

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Voloridge Investment Management's HRTX Position: Q4 2021 in Review

Voloridge Investment Management sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 11,933 shares — an estimated $128K sold.

Voloridge Investment Management first reported a position in HRTX in Q2 2015 and held it in 9 quarters. The position peaked at $3.96M in Q4 2019. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

Voloridge Investment Management reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
Voloridge Investment Management sold 11,933 Heron Therapeutics shares in Q4 2021, an estimated $128K.
Voloridge Investment Management first reported a position in Heron Therapeutics in Q2 2015 and held it in 9 quarters.
Voloridge Investment Management's Heron Therapeutics position peaked at $3.96M in Q4 2019.
200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on Voloridge Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.